Skip to main content
Up to 53% offSee the plans

News | Stocks | Iran

Caspian Tamin Pharmaceutical (KSPZ) Lifts Six-Month Net Profit 296% to 37,395 Billion Rials at a 76.3% Gross Margin

Sahmino Newsroom | 19 November 2026 | yesterday

KSPZdown1.1%42,450rials18 November

In its standalone income statement for the six months to 31 Shahrivar 1405 (22 September 2026), filed on Codal on 19 November 2026, Caspian Tamin Pharmaceutical (KSPZ) reported operating revenue of 68,123 billion rials, up 210% from 21,960 billion rials in the same period a year earlier (restated).

Gross profit grew 256% to 51,964 billion rials, and the gross margin rose from 66.4% to 76.3%. Operating profit came to 51,091 billion rials (up 259%) and net profit to 37,395 billion rials, against 9,435 billion rials a year earlier. Basic earnings per share went from 1,189 to 4,724 rials, and the six-month net profit equals 171% of the full-year profit for fiscal 1404 (21,813 billion rials, an unaudited column in the same letter).

Income tax was 10,782 billion rials (2,913 billion rials a year earlier) and finance costs 3,059 billion rials. Share capital is 7,940 billion rials.

Reference:CodalThe original report

Sahmino context

What the prices have done since this story was published, and what Sahmino wrote around it

Sahmino's reading

KSPZ closed on Wednesday 18 November at 42,280 rials, 4.5% above its 24 October close of 40,470 rials and 3.9% below its 52-week high of 43,980 rials (17 November). The exchange P/E on that close is 6.83 against 7.39 for its sector, struck on a trailing EPS of 6,189 rials that predates this filing (nightly reading of 17 November).

More from this market